相关实验视频

Updated: May 6, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

前列腺癌周围神经侵袭的转录形状识别了预后基因特征

Cagdas Aktan¹, Swati Mamidanna², Caryn Cobb³

¹Department of Medical Biology, Faculty of Medicine, Bandirma Onyedi, Eylul University, Balikesir 10250, Türkiye.

|August 28, 2025

概括

与周围神经侵入 (PNI) 相关的前列腺癌的基因组变化可能预测疾病的进展. 识别这些遗传标记,如AZGP1,ASPN,COMP,RYR2和SFRP4,可以帮助评估前列腺切除术后的风险.

科学领域:

癌症学
基因组学
前列腺癌研究

背景情况:

前列腺癌是一种普遍存在的男性恶性瘤,具有影响预后的多种组织病理特征.
周围神经侵袭 (PNI) 是一个公认的前列腺癌的标志.
了解与PNI相关的基因组变化对于预测疾病行为至关重要.

研究的目的:

在前列腺癌患者中调查与周围神经侵入 (PNI) 相关的基因组变化.
确定与PNI状态和患者存活率相关的特定基因.
评估根性前列腺切除术后发现的这些基因组变化的预后意义.

主要方法:

来自癌症基因组图谱的421名前列腺癌患者的回顾性分析,
在患有周围神经侵袭 (PNI) 患者之间识别不同表达的基因.
使用统计模型分析关键基因的mRNA表达水平及其与无疾病生存的相关性.

主要成果:

在PNI瘤中显著增加了COL9A3,ASPN,ESR1,MUC1,PIP,SFRP4,KRT19,CLDN1和COMP的mRNA表达.
在没有PNI的瘤中观察到RYR2,MME和AZGP1的高表达.
高AZGP1表达与更长的无病生存时间相关;高ASPN,COMP,RYR2和SFRP4表达与更短的生存时间相关.

结论:

在前列腺癌中与PNI相关的基因组变化可能表明前列腺切除术后进展的风险增加.
特定的基因表达特征可以作为预测疾病复发的潜在生物标志物.
需要进一步的前性研究来验证这些基因组发现及其临床影响.

关键词:

周围神经的入侵预后生物标志物前列腺癌

更多相关视频

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...